MIRM Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
185.7M
+5.4%
176.2M
+10.2%
159.9M
+7.4%
148.9M
+12.0%
133.0M
Cost of Revenue
35.2M
+15.9%
30.3M
+5.4%
28.8M
+1.9%
28.3M
+10.7%
25.5M
Gross Profit
150.5M
+3.2%
145.9M
+11.3%
131.1M
+8.6%
120.7M
+12.3%
107.5M
Operating Expenses
210.3M
+11.6%
188.4M
-79.5%
920.5M
+635.1%
125.2M
+19.4%
104.9M
R&D
121.4M
+13.5%
107.0M
-87.0%
824.2M
+1512.7%
51.1M
+19.0%
43.0M
SG&A
88.9M
+9.1%
81.5M
-15.4%
96.3M
+30.0%
74.1M
+19.7%
61.9M
Operating Income
-59746000
-40.5%
-42537000
+94.6%
-789465000
-17186.3%
-4567000
-275.5%
2.6M
EBITDA
-52857000
-48.5%
-35601000
+95.5%
-782591000
-52030.4%
1.5M
-82.6%
8.7M
Net Income
-40766000
+39.4%
-67227000
+91.5%
-790155000
-13689.8%
-5730000
-297.2%
2.9M
EPS (Basic)
$-0.62
+41.5%
$-1.06
+92.1%
$-13.43
-12109.1%
$-0.11
-283.3%
$0.06
EPS (Diluted)
$-0.62
+41.5%
$-1.06
+92.1%
$-13.43
-10230.8%
$-0.13
-360.0%
$0.05
Shares (Diluted)
66.0M
+4.2%
63.4M
+7.7%
58.9M
+30.2%
45.2M
-20.7%
57.0M
Mirum Pharmaceuticals (MIRM) — Financials